The GPRD is a widely used resource for studies in drug safety and pharmacoepidemiology.
CONCLUSION
The
GPRD is a widely used resource for studies in drug safety and
pharmacoepidemiology. The GPRD is main-tained and developed by the MHRA. The
challenge is that analyses of GPRD data require a deep under-standing of both
the GPRD and the UK health care system. For example, there have been major
changes in the reporting and collection of some laboratory data. Collaboration
with researchers who understand the GPRD and the UK health care system may be
helpful.
The
GPRD is used by researchers internationally in academia, the pharmaceutical
industry, the NHS and UK Government Departments for research in areas such as
disease epidemiology, drug/vaccine util-isation and safety, pharmacoeconomics
and resource utilisation. Its value in pharmacoepidemiology is highlighted by
its ongoing use by drug regulatory authorities – namely the US Food and Drugs
Admin-istration (FDA) as well as the Post Licensing Division of the MHRA. Over
500 papers have been published in peer-reviewed journals testifying to the quality
of the data. A bibliography can be found on the GPRD website (www.gprd.com).
General
Practice Research Database is indebted to the GPs who contribute the data from
their clinical system; INPS, the supplier of the Vision software computer
system, used by contributing GPs; and the members of the Scientific Ethical
Advisory Group (SEAG) and the recent replacement group ISAC who give necessary
oversight to the research conducted in GPRD.
In conclusion, GPRD is highly valuable for stud-ies in drug
safety and pharmacoepidemiology. Future developments will enable even higher
standards of data collections and access to other data sets. The challenge is
not only to further improve the granu-larity of information available in GPRD
but also to enhance our methods for analysing these data.
Related Topics
TH 2019 - 2024 pharmacy180.com; Developed by Therithal info.